AstraZeneca shares rise

AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company confirmed that its Chinese business is under investigation for alleged unpaid import taxes on certain cancer drugs, including Imfinzi (durvalumab) and Imjudo (tremelimumab).
AstraZeneca shares rise as China probe update reassures
Investors were reassured after the drugmaker said a potential fine in China would have only a minor business impact.The company said it could face a charge of up to $4.5 million in the country over suspected unpaid import taxes for two cancer drugs.
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more
AstraZeneca faces potential fines in China over import taxes
Drugmaker AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales of cancer drugs helped drive revenues higher. At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
AstraZeneca sales jump despite troubles in China
UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024. AstraZeneca ’s $14.
AstraZeneca shareholders say they need clarity on China investigations
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (NASDAQ:AZN) shares gained in European trading on Thursday after the Anglo-Swedish drugmaker reported better-than-expected Q4 2024 results and addressed investor concerns over an investigation the company is facing in China.
AstraZeneca CEO says company has no access to executive Wang, in detention in China
AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...
Pharmaceutical giant AstraZeneca faces potential fines in China over import taxes
AstraZeneca appointed a new president for its China operations following the arrest of former executive Leon Wang along with ...
STAT15h
Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super Bowl ...
FiercePharma16h
AstraZeneca warns of potential tax fines amid China sales slowdown, illegal drug importation probe
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site
The boss of drugmaker AstraZeneca has said he was “very disappointed” with the firm’s move to scrap plans for a £450 million ...
Revenues, profits surge at AstraZeneca
AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.
AstraZeneca continues to ‘fully cooperate’ with Chinese authorities
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...